Management of Irbesartan Therapy

Critical Thresholds for Holding Irbesartan

• The European Society of Cardiology recommends holding irbesartan immediately when potassium rises to ≥6.0 mEq/L or when serum creatinine increases to >220 μmol/L (2.5 mg/dL) 1, 2
• For patients with potassium levels between 5.5-6.0 mEq/L, the European Heart Journal suggests halving the dose of irbesartan and monitoring blood chemistry closely 1

Contraindications to Continuation

• The American Heart Association recommends discontinuing irbesartan in patients with baseline potassium >5.0 mEq/L or eGFR <30 mL/min/1.73 m² due to potential harm 6, 7
• The European Journal of Heart Failure advises against using ARBs in patients already on both an ACE inhibitor and aldosterone antagonist due to excessive hyperkalemia risk 5, 1

Monitoring Requirements and Dose Adjustment Algorithm

• The European Journal of Heart Failure recommends checking renal function and serum electrolytes within 1 week of starting treatment and rechecking at 1 and 4 weeks after any dose increase 5, 1
• The Kidney International journal suggests monitoring patients more frequently, especially those on concurrent aldosterone antagonists, with baseline eGFR 30-49 mL/min/1.73 m², or elderly patients 4

Alternative Strategies to Avoid Holding

• The Kidney International journal recommends considering potassium binders or potassium-wasting diuretics to reduce serum potassium and enable continued use of ARB therapy 4
• The European Heart Journal suggests adding SGLT2 inhibitors to reduce hyperkalemia risk in patients on RAAS inhibitors 3